News

Bioplastics market to triple
Enlarge image

StudyGermany

Bioplastics market to triple

08.03.2013 - Bio-based polymers production capacity will triple to nearly 12 million tonnes in 2020, says study.

According to the largest ever market study published, bio-based drop-in PET and PE/PP polymers and the new polymers PLA and PHA show the fastest rates of market growth. However, Europe will stand only at the sidelines as the lion’s share of capital investment is expected to take place in Asia and South America, says the study conducted by the Cologne-based Nova Institute.

The global survey of 247 companies covered every kind of bio-based polymer and examines 114 companies in detail. Considerably higher production capacity was found compared to earlier studies. The Nova experts identified that there was a production capacity of 3.5 million tonnes in 2011 – a share of 1.5% of overall construction polymer production. According to estimates of the surveyed manufacturers, production capacity will raise to nearly 12 million tonnes by 2020. With an expected total polymer production of about 400 million tonnes in 2020, the bio-based share should increase from 1.5% in 2011 to 3% in 2020, meaning that bio-based production capacity will grow faster than overall production.

The most dynamic development is anticipated in drop-in biopolymers, which are chemically identical to their petrochemical counterparts but are at least partially derived from biomass. This group is spearheaded by partly bio-based PET (Bio-PET) of which production capacity will reach about 5 million tonnes by the year 2020, using bioethanol from sugar cane. The second in this group are bio-based polyolefins like PE and PP, also based on bioethanol. But “new in the market” bio-based polymers PLA and PHA are also expected to at least quadruple the capacity between 2011 and 2020. Most investment in new bio-based polymer capacities will take place in Asia and South America because of better access to feedstock and a favourable political framework. Europe’s share will decrease from 20% to 14% and North America’s share from 15% to 13%, whereas Asia’s will increase from 52% to 55% and South America’s from 13% to 18%. So world market shares are not expected to shift dramatically, which means that every region of the world will experience development in the field of bio-based polymer production.

© eurobiotechnews.eu/tg

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

RegulationUKEU

29.07.2014 The first vaccine for malaria may be within reach: The European Medicines Agency has accepted Glaxosmithkline’s malaria vaccine candidate RTS,S for regulatory review.

FundingEU

25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.09 SEK12.50%
  • WILEX (D)2.99 EUR6.79%
  • CO.DON (D)2.75 EUR5.77%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.99 EUR251.8%
  • ADDEX (CH)3.82 CHF59.2%
  • 4SC (D)1.45 EUR49.5%

FLOP

  • HYBRIGENICS (F)1.72 EUR-29.5%
  • PROSENSA (NL)9.72 USD-23.4%
  • PROTHENA PLC (IE)17.37 USD-22.1%

TOP

  • SANTHERA (CH)64.00 CHF3037.3%
  • GW PHARMACEUTICALS (UK)426.00 GBP667.6%
  • PAION (D)2.67 EUR292.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.6%
  • CYTOS (CH)0.28 CHF-91.7%
  • THROMBOGENICS (B)9.14 EUR-70.4%

No liability assumed, Date: 30.07.2014